Induction of HCA587-Specific Antitumor Immunity with HCA587 Protein Formulated with CpG and ISCOM in Mice

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Chen, Juanjuan ^a   Zhang, Lijie ^a   Wen, Weigang ^a   Hao, Jiaqing ^a   Zeng, Pumei ^a   Qian, Xiaoping ^a   Zhang, Yu ^a   Yin, Yanhui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HCA 587 PROTEIN VACCINE; ISCOM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; ESCHERICHIA COLI; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; ISCOMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS;

EID: 84867427222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047219     Document Type: Article

References (52)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
2. Jahnisch H, Fussel S, Kiessling A, Wehner R, Zastrow S, et al. (2010) Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol 2010: 517493-517500.
3. Gilboa E, (2004) The promise of cancer vaccines. Nat Rev Cancer 4: 401-411.
4. Schietinger A, Philip M, Schreiber H, (2008) Specificity in cancer immunotherapy. Semin Immunol 20: 276-285.
5. Caballero OL, Chen YT, (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100: 2014-2021.
6. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, et al. (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37: D816-819.
7. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, et al. (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105: 1650-1655.
8. Carrasco J, Van Pel A, Neyns B, Lethe B, Brasseur F, et al. (2008) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180: 3585-3593.
9. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, et al. (2008) Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 31: 849-857.
10. Li B, Wu HY, Qian XP, Li Y, Chen WF, (2003) Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells. World J Gastroenterol 9: 678-682.
11. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, et al. (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201: 241-248.
12. Li B, He X, Pang X, Zhang H, Chen J, et al. (2004) Elicitation of both CD4 and CD8 T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells. Scand J Immunol 60: 506-513.
13. Li B, Wang Y, Chen J, Wu H, Chen W, (2005) Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin Exp Immunol 140: 310-319.
14. Xing Q, Pang XW, Peng JR, Yin YH, Li Y, et al. (2008) Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem Biophys Res Commun 372: 331-335.
15. Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, et al. (2007) A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol Immunother 56: 753-759.
16. Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, et al. (2004) Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer 109: 698-702.
17. Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, et al. (2011) A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int J Cancer 129: 2427-2434.
18. Wen W, Zhang L, Peng J, Chen J, Hao J, et al. (2011) Identification of promiscuous HLA-DR-restricted CD4 T-cell epitopes on the cancer-testis antigen HCA587. Cancer Sci 102: 1455-1461.
19. Li B, Qian XP, Pang XW, Zou WZ, Wang YP, et al. (2003) HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma. Lab Invest 83: 1185-1192.
20. Lucas S, De Plaen E, Boon T, (2000) MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer 87: 55-60.
21. Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, et al. (2002) Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169: 1102-1109.
22. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, et al. (2009) Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 124: 352-357.
23. Kariyama K, Higashi T, Kobayashi Y, Nouso K, Nakatsukasa H, et al. (1999) Expression of MAGE-1 and-3 genes and gene products in human hepatocellular carcinoma. Br J Cancer 81: 1080-1087.
24. Xu H, Gu N, Liu ZB, Zheng M, Xiong F, et al. (2012) NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett 3: 39-44.
25. Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, et al. (2006) Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 21: 1281-1285.
26. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, et al. (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201: 249-257.
27. Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y, et al. (2006) Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun 6: 7.
28. Pang YL, Zhang HG, Peng JR, Pang XW, Yu S, et al. (2009) The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol Immunother 58: 877-886.
29. Jensen FC, Savary JR, Diveley JP, Chang JC, (1998) Adjuvant activity of incomplete Freund's adjuvant. Adv Drug Deliv Rev 32: 173-186.
30. Pearse MJ, Drane D, (2005) ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 57: 465-474.
31. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM, (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10: 499-511.
32. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, et al. (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180: 3132-3139.
33. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, et al. (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63: 4095-4100.
34. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, et al. (2000) The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46Suppl: S52-61.
35. Knutson KL, Disis ML, (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54: 721-728.
36. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, et al. (2005) Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117: 596-604.
37. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, et al. (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172: 3289-3296.
38. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV, (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186: 1623-1631.
39. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
40. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
41. Haanen JB, Baars A, Gomez R, Weder P, Smits M, et al. (2006) Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55: 451-458.
42. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
43. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, et al. (2006) Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107: 2866-2872.
44. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, et al. (2008) Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 44: 1875-1882.
45. Steitz J, Bruck J, Lenz J, Knop J, Tuting T, (2001) Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61: 8643-8646.
46. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
47. Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, et al. (2003) [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy]. Bull Cancer 90: 677-685.
48. Klebanoff CA, Gattinoni L, Restifo NP, (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224.
49. Hinrichs CS, Gattinoni L, Restifo NP, (2006) Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 18: 363-370.
50. Muranski P, Restifo NP, (2009) Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 21: 200-208.
51. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, et al. (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207: 637-650.
52. Kennedy R, Celis E, (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222: 129-144.